AOCNP Advanced Oncology Certified Nurse Practitioner 2

Question 1

A patient receiving FOLFOX chemotherapy develops grade 3 peripheral neuropathy. What is the most appropriate management?

Accepted Answer

Discontinue oxaliplatin permanently

Answer

Grade 3 peripheral neuropathy from oxaliplatin warrants permanent discontinuation of oxaliplatin to prevent irreversible nerve damage.

Question 2

Which tumor suppressor gene is most commonly mutated in hereditary breast-ovarian cancer syndrome?

Accepted Answer

BRCA1/BRCA2

Answer

BRCA1 and BRCA2 mutations account for the majority of hereditary breast-ovarian cancer syndrome cases.

Question 3

A patient with metastatic melanoma is started on ipilimumab and develops colitis with diarrhea >7 stools/day above baseline. What is the first-line treatment?

Accepted Answer

IV methylprednisolone 1-2 mg/kg/day

Answer

Grade 3-4 immune-related colitis requires high-dose IV corticosteroids as initial therapy.

Question 4

What is the mechanism of action of venetoclax in hematologic malignancies?

Accepted Answer

Blocks BCL-2 anti-apoptotic protein

Answer

Venetoclax is a selective BCL-2 inhibitor that restores apoptosis in cancer cells that overexpress this anti-apoptotic protein.

Question 5

A postmenopausal woman with ER+/HER2- early breast cancer completes 5 years of tamoxifen. What is the recommended next step?

Accepted Answer

Switch to an aromatase inhibitor for up to 5 additional years

Answer

Extended adjuvant therapy with an aromatase inhibitor for up to 5 additional years after tamoxifen reduces late recurrence in postmenopausal patients.

AOCNP - Advanced Oncology Certified Nurse Practitioner Practice Test

AOCNP - Advanced Oncology Certified Nurse Practitioner Practice Test

AOCNP Advanced Oncology Certified Nurse Practitioner 2